CAMBRIDGE, Massachusetts and AMSTERDAM, February 20, 2013 /PRNewswire/ --
uniQure has been identified in the field of biomedicine as one of 2013's 50 Disruptive Companies, MIT Technology Review's annual list of the world's most innovative technology companies. The honorees are nominated by MIT Technology Review's editors, who look for companies that have demonstrated original and valuable technology over the last year, are bringing that technology to market at significant scale, and are clearly influencing their competitors. Spanning energy and materials, Internet and digital media, computing and communications, biomedicine, and transportation, the 50 companies on the list represent the disruptive innovations most likely to change our lives.
Jason Pontin , publisher and editor in chief of MIT Technology Review, states, "The pace at which technology changes is astounding. This issue celebrates organizations at the forefront, displaying 'disruptive innovation' that will prove to surpass the competition, transform an industry, and change our lives. uniQure proves they are one of those companies by restoring the promise of gene therapy with the approval to treat rare metabolic disorders."
uniQure is the world leader in the development of human gene based therapies. uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency was approved in the European Union in November 2012, and is the first approved gene therapy in the Western world.
"We are honored by the recognition of MIT Technology Review," says J
Copyright©2012 PR Newswire.
All rights reserved